Table 9Comparison of disease-modifying drugs at 2 years in observational data60

TrialOutcome measureInterferon β-1bInterferon β-1a SCInterferon β-1a IMGlatiramer acetateP value
Haas, 2005
N=283
24 months
Annualized relapse rate0.690.660.80.36P<0.001
% Relapse-free45.545.835.458.2P=0.22
Discontinued treatment 6–24 mos22.931.232.98.9P<0.001
% Progression-free71.773.374.587.5P=0.13
Castelli-Haley, 2008
N=845 ITT
N=410 continuous use group
Annualized relapse rateNRNR
ITT group

Continuous use group
0.054

0.045
0.03

0.009
P=0.035

P=0.005

Abbreviations: IM, intramuscular; ITT, intention-to-treat; mo, month; NR, not reported; SC, subcutaneous.

From: Results

Cover of Drug Class Review: Disease-modifying Drugs for Multiple Sclerosis
Drug Class Review: Disease-modifying Drugs for Multiple Sclerosis: Final Update 1 Report [Internet].
Smith B, Carson S, Fu R, et al.
Portland (OR): Oregon Health & Science University; 2010 Aug.
Copyright © 2010 by Oregon Health & Science University, Portland, Oregon 97239. All rights reserved.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.